ASCO 2018 | Immuno-oncology agents for MM: checkpoint inhibitors and NK-cells

Noopur Raje

The use of checkpoint inhibitors in multiple myeloma (MM) is an exciting area. The data from two KEYNOTE studies examining this are discussed here by Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA: KEYNOTE-185 (NCT02579863), investigating pembrolizumab in the frontline setting; and KEYNOTE-183 (NCT02576977), which looked at prembrolizumab plus pomalidamide and dexamethasone in the relapsed/refractory setting. Prof. Raje highlights the factors that must be taken into account when using checkpoint inhibitors in MM. Lastly, she covers the trial (NCT01729091) of a umbilical cord blood‐derived NK-cell therapy for MM patients undergoing high dose chemotherapy and auto‐HSCT. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video